Abstract. Fucoxanthin is a carotenoid that is mainly identified in brown algae and is known to have anticarcinogenic and anti-tumor activities. Carotenoids have generally been shown to induce the expression and enzyme activity of the cytochrome P450s (CYPs). The present study evaluated the effect of fucoxanthin on the expression and enzymatic activity of the major xenobiotic metabolizing enzymes, CYP1A1, CYP1A2 and CYP3A4. Fucoxanthin markedly induced the expression of cyp1a1 mRNA in HepG2 cells, but inhibited its enzyme activity in the cells and in vitro. Fucoxanthin also inhibited the enzyme activity of CYP1A2 and CYP3A4 in a dose-dependent manner in vitro. These results suggest that fucoxanthin may serve as a useful agent in cancer prevention with less adverse effects than β-carotene, including the activation of pro-carcinogens by CYPs.

Introduction

Epidemiological and animal studies have shown that carotenoids possess cancer preventive and tumor inhibitory activities. However, clinical trials using β-carotene have resulted in the induction of lung cancer in male heavy smokers and asbestos workers, thus raising complex questions pertaining to the properties of carotenoids (1). Extensive research concerning the action of carotenoids is required in order to elucidate the effects of carotenoids on human health. Although the mechanism by which β-carotene increases the incidence of lung cancer remains to be elucidated, it has been speculated that the expression of the cytochrome P450 (CYP) enzymes, including CYP1A1/2 and CYP3A, that is induced by β-carotene may be responsible for the activation of pro-carcinogens and thus, the increase in the risk of lung cancer (2).

Material and methods

Chemicals. Fucoxanthin (Fig. 1) was isolated as previously described (23) and was obtained from Dr Yoshito Tanaka (Faculty of Fisheries, Kagoshima University, Japan). The fucoxanthin was dissolved in dimethyl sulfoxide. Positive controls, 3-methylcholanthrene (3-MC), a known CYP1A1/2 inducer, omeprazole, a known CYP1A1 inhibitor, α-naphthoflavone, a known CYP1A2 inhibitor and ketoconazole, a known CYP3A4 inhibitor, were purchased from Sigma-Aldrich (Tokyo, Japan). 7-Ethoxyresorufin was also purchased from Sigma-Aldrich. All other chemicals were of biological grade.
**Cell culture.** Human hepatocellular carcinoma HepG2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS). The cells were maintained in an incubator at 37˚C under a humidified atmosphere comprising 5% CO₂. The cell viability was determined using the trypan blue dye exclusion test.

**Northern blot analysis.** Total RNA was extracted from the cells. A total of 20 µg total RNA was electrophoresed and transferred to a nylon membrane. Northern blots were hybridized with a 32P-labeled probe. PCR was performed to generate a cDNA probe for the cyp1a1 gene (GenBank accession no. NM_00049). The data was normalized to the level of 36b4 expression.

**Measurement of CYP1A1/2 activity in HepG2 cells.** The cells were plated at a density of 3x10⁴ cells/100 µl medium in 96-well plates. Subsequent to 24 h, the cells were treated with fucoxanthin or other chemicals, including phytoene and β-carotene, for another 24 h. CYP activity was determined using the P450-Glo CYP1A1 assay (Promega KK, Tokyo, Japan), according to the manufacturer's instructions, and the 7-ethoxyresorufin-O-deethylase (EROD) assay. For the P450-Glo assay, the cells were washed twice with phosphate-buffered saline without Ca²⁺ and Mg²⁺ (PBS; -), and serum-free medium containing 50 µM luminogenic CYP1A1-specific substrate and luciferin-6'-chloroethyl ether was added. The cells were incubated at 37˚C for 3 h, following which, 50 µl medium from each well was mixed with a luciferin detection reagent and the mixture was incubated at room temperature for 20 min. The luminescence was measured using a SpectraMax M5 microplate reader (Molecular Devices, Tokyo, Japan). The EROD assays were performed as previously described (24). Briefly, the cells were washed twice with PBS (-), and then 5 µM ethoxyresorufin and 1.5 mM salicylamide in a serum-free medium were added. Following incubation for 1 h at 37˚C, the fluorescence was measured, with excitation at 560 nm and emission at 595 nm, using a SpectraMax M5 microplate reader. The CYP activity was expressed as luminescence/protein (P450-Glo assay) or fluorescence/protein (EROD assay) in each sample. The protein content of the samples was determined using a BCA Protein Assay kit (Pierce, Rockford, IL, USA).

**Measurement of CYP1A1/2 and CYP3A4 activity in vitro.** CYP1A1 activity was determined using the P450-Glo CYP1A1 assay (Promega KK) and CYP1A2 and CYP3A4 activities were determined using Vivid CYP450 Screening kits (Life Technologies, Tokyo, Japan), according to the manufacturer's instructions. Microsomes containing the human CYP1A1 isoform (recombinant) were purchased from Sigma-Aldrich. For the P450-Glo assays, a 50 µl reaction mixture containing 0.5 pmol CYP1A1, 400 mM KPO₄ buffer and 120 mM luciferin-6'-chloroethyl ether, a luminogenic CYP1A1-specific substrate, was mixed with an equal volume of test compound and the mixture was incubated at room temperature for 10 min. Following this, an equal volume of NADPH regenerating system solution (2.6 mM NADP⁺, 6.6 mM glucose-6-phosphate, 6.6 mM MgCl₂ and 0.8 U/ml glucose-6-phosphate dehydrogenase) was added. The reaction mixture was incubated at room temperature for 30 min. Luciferin detection reagent was then added and the mixture was incubated at room temperature for 20 min. The luminescence was then measured using a microplate reader. For the Vivid CYP450 Screening kit assay, the test compound was mixed with a master pre-mix comprising CYP450 BACULOSOMES® reagent and regeneration system, which contained glucose-6-phosphate and glucose-6-phosphate dehydrogenase. The mixture was incubated at room temperature for 20 min. Following incubation, each CYP enzyme-specific substrate (Vivid EOMCC for CYP1A2 or Vivid DBOMF for CYP3A4) and NADP⁺ were added and the mixture was incubated at room temperature for 30 min. The reaction was stopped by the addition of 3 µM α-naphthoflavone (for CYP1A2) or 10 mM ketoconazole (for CYP3A4). CYP activity was evaluated by measuring the fluorescence of the fluorescent metabolite generated from each CYP enzyme-specific substrate. The fluorescence was measured using a microplate reader.

**Statistical analysis.** The data were analyzed using Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Inductive effect of fucoxanthin on the expression of the cyp1a1 gene in HepG2 cells.** Fucoxanthin dramatically induced the expression of cyp1a1 in a dose-dependent and time-dependent manner (Fig. 2). At 24 h post-treatment with 16.5 µM fucoxanthin, cyp1a1 was induced 5.9-fold compared with the control. Fucoxanthin (16.5 µM) induced the expression of cyp1a1 as early as 8 h after the treatment (not significant) and the inductive effect increased markedly at 48 h and continued up to 72 h (85.6-fold compared with the control). cyp1a2 was not enhanced (data not shown) and cyp3a4 was not expressed in the HepG2 cells.

**Inhibitory effect of fucoxanthin on CYP1A1/2 enzyme activity in HepG2 cells.** Fucoxanthin (11 µM) significantly decreased CYP1A1 enzyme activity in the HepG2 cells (Fig. 3). In contrast, 3-MC, a known cyp1a1 gene inducer, significantly induced CYP1A1 enzyme activity, while other carotenoids, including phytoene and β-carotene, demonstrated no inhibitory effect on CYP1A1 enzyme activity (data not shown). Furthermore, the EROD assay, which measures CYP1A1 and CYP1A2 activity, revealed the same results (Fig. 4). The data suggest that fucoxanthin is able to inhibit the activity of CYP1A1 and CYP1A2.

**Inhibitory effect of fucoxanthin on human recombinant CYP enzyme activity.** The inhibition of CYP enzyme activity by

---

**Figure 1. Structure of fucoxanthin.**

---

SATOMI and NISHINO: FUCOXANTHIN INHIBITS CYP ENZYME ACTIVITY
Fucoxanthin was measured using a specific substrate (Fig. 5). Fucoxanthin (12 µM) significantly inhibited CYP1A1 activity, although the inhibition was weaker than that of omeprazole, a known CYP1A1 inhibitor. Similarly, fucoxanthin (45 µM and 9 µM) significantly inhibited CYP1A2 and CYP3A4 activity, respectively, though the inhibition was weaker than that of α-naphthoflavone, a known CYP1A2 inhibitor, and of α-naphthoflavone (30 nM) and ketoconazole (0.1 µM) were used as positive controls for each CYP enzyme. CYP, cytochrome P450; Fx, fucoxanthin; OMP, omeprazole; α-NF, α-naphthoflavone; Keto, ketoconazole; RLU, relative luminescence unit. Data are expressed as the mean ± SD (n=3-5). *P<0.01 and **P<0.001 vs. the control.

Figure 4. Effect of fucoxanthin on the EROD activity in HepG2 cells. The cells were treated with fucoxanthin for 24 h and the EROD activity was measured. 3-MC (2.5 µM) was used as a positive control. Fx, fucoxanthin; 3-MC, 3-methylcholanthrene; EROD, 7-ethoxyresorufin-O-deethylase. Data are expressed as the mean ± SD (n=3-5). *P<0.01 and **P<0.001 vs. the control.
ketoconazole, a known CYP3A4 inhibitor. CYP1A1, CYP1A2 and CYP3A4 enzyme activity was inhibited by fucoxanthin in a dose-dependent manner, with IC50 values of 12.5, 49.0 and 11.0 µM, respectively (Fig. 6). The inhibitory effect of fucoxanthin on CYP1A2 was slightly weaker compared with CYP1A1 and CYP3A4. Lineweaver-Burk plots showed that fucoxanthin was not a competitive inhibitor for all the CYP enzymes that were examined (Fig. 7).

Discussion

In an effort to ascertain the role of fucoxanthin in cancer prevention, the present study evaluated the effect of fucoxanthin on the enzyme activities of CYP1A1, 1A2 and 3A4, which are known to be involved in the activation of pro-carcinogens. Since carotenoids are known to induce phase I enzymes, including CYP1A1, they may enhance cancer initiation under certain conditions. The intake of β-carotene supplements has been reported to increase the incidence of lung cancer in male smokers and asbestos workers (1). One hypothesis put forward to account for this involved the induction of CYP enzymes by β-carotene (2,25).

In the present study, fucoxanthin significantly induced cyplal mRNA (Fig. 2), but inhibited CYP1A1 enzyme activity (Fig. 3), in the HepG2 cells. The EROD assay also demonstrated that fucoxanthin inhibited CYP1A1/2 activity, in HepG2 cells (Fig. 4). The data suggest that fucoxanthin may inhibit specific CYP enzyme activity, regardless of its inductive effect on expression.

The effect of fucoxanthin on the enzyme activity of recombinant human CYPs (CYP1A1, CYP1A2 and CYP3A4) was also analyzed in vitro. Fucoxanthin inhibited the activity of these CYPs, though the effect was weaker compared with known inhibitors, including omeprazole for CYP1A1, α-naphthoflavone for CYP1A2 and ketoconazole for CYP3A4 (Fig. 5). Few studies have examined the potential of carotenoids in the inhibition of CYP enzyme activity. Lycopene has been shown to inhibit the activity of CYP1A1 and CYP1B1 (17).
Fucoxanthin has also been described as inhibiting CYP3A4 enzyme activity in HepG2 cells (15). However, the present study was unable to detect CYP3A4 activity or CYP3A4 mRNA expression in the HepG2 cells. Alterations in the nature of the cells utilized between laboratories may account for this discrepancy. In any case, fucoxanthin was shown to inhibit the activity of CYP1A1, CYP1A2 and CYP3A4.

The mechanism by which fucoxanthin inhibits the activity of the aforementioned CYPs remains to be delineated. Lineweaver-Burk plots revealed that fucoxanthin is not a competitive inhibitor of these CYPs (Fig. 7). Wang H et al showed that lycopene competitively inhibited CYP1A1 and CYP1B1 enzymes (17). Although diverse compounds may be acted upon by these CYPs, the main substrates of CYP1A1, CYP1A2 and CYP3A4 are polycyclic hydrocarbons, amines and steroids, respectively, and include a number of drugs. Thus, certain carotenoids may act as competitive inhibitors of CYPs. However, the present study did not observe that fucoxanthin was a competitive inhibitor of these CYPs. Fucoxanthin may attenuate CYP enzyme activity through an allosteric mechanism.

In conclusion, the present data suggested that fucoxanthin inhibits CYP1A1, CYP1A2 and CYP3A4 enzyme activity and that these inhibitory effects may contribute towards the cancer preventive action of fucoxanthin. The data also suggested that fucoxanthin may attenuate the action of certain drugs activated by CYP3A4 through the inhibition of CYP3A4. Further research is required with regard to the underlying mechanism of the inhibitory action of fucoxanthin on CYP enzyme activity.

Acknowledgements

This study was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (No. 20590610).

References

1. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh J P, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cernick MG, Brodkin CA and Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88: 1550-1559, 1996.

2. Paolini M, Cantelli-Forti G, Perocco P, Pedulli GF, Abdel-Rahman SZ and Legator MS: Co-carcinogenic effect of 16alpha-fluoro-5-androsten-3-ol, a natural carotenoid, on N-ethyl-N'-nitro-N-nitrosoguanidine-induced mouse lung and colon carcinogenesis. Cancer Lett 68: 159-168, 1993.

3. Nebert DW, Wikvall K and Miller WL: Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci 368: 20120431, 2013.

4. Zhang JY, Wang Y and Prakash C: Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7: 939-948, 2006.

5. Shimada T: Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. Drug Metab Pharmacokinet 21: 257-276, 2006.

6. Shimada T and Fuji-Kuniyama Y: Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 95: 1-6, 2004.

7. Ma Q and Lu AY: CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 35: 1009-1016, 2007.

8. Zhou SF, Xue CC, Yu XQ and Wang G: Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 8: 526-533, 2007.

9. Ohno M, Darwish WS, Ikemaka Y, Miki W and Ishizuka M: Astaxanthin can alter CYP1A-dependent activities via two different mechanisms: induction of protein expression and inhibition of NADPH P450 reductase dependent electron transfer. Food Chem Toxicol 49: 285-1291, 2011.

10. Gradelet S, Astorg P, Pineau T, Canivenc M, Siess MH, Leclerc J and Lesca P: Ah receptor-dependent CYP induction by two carotenoids, canthaxanthin and b-apo-8-carotenal, with no affinity for the TCDD binding site. Biochem Pharmacol 54: 307-315, 1997.

11. Breinholt V, Lauridsen ST, Daneshvar B and Jakobsen J: Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett 154: 201-210, 2006.

12. Zhang JY, Wang Y and Prakash C: Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab 7: 939-948, 2006.

13. Guengerich FP: Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 35: 29-46, 2013.

14. Paolini M, Cantelli-Forti G, Perocco P, Pedulli GF, Abdel-Rahman SZ and Legator MS: Co-carcinogenic effect of 16alpha-fluoro-5-androsten-3-ol, a natural carotenoid, on N-ethyl-N'-nitro-N-nitrosoguanidine-induced mouse lung and colon carcinogenesis. Cancer Lett 68: 159-168, 1993.

15. Liu CL, Lim YP and Hu ML: Fucoxanthin attenuates rifampin-induced cytochrome P450 3A4 (CYP3A4) and multiple drug resistance 1 (MDRI) gene expression through pregnane X receptor (PXR)-mediated pathways in human hepatoma HepG2 and colon adenocarcinoma LS174T cells. Mar Drugs 10: 242-257, 2012.

16. Firdous AP, Sindhu ER, Ramnath V and Kuttan R: Anti-mutagenic and anti-carcinogenic potential of the carotenoid meso-zeaxanthin. Asian Pac J Cancer Prev 11: 1795-1800, 2010.

17. Wang H and Leung LK: The carotenoid lycopene differentially regulates phase I and II enzymes in dimethylbenz[a]anthracene-induced MCF-7 cells. Nutrition 26: 1181-1187, 2010.

18. Gradelet S, Astorg P, Le Bon AM, Bergès R and Suschetet M: Modulation of aflatoxin B1 carcinogenicity, genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1A inducers. Cancer Lett 144: 221-232, 1999.

19. Kim KN, Ahn G, Heo SJ, Kang SM, Kang MC, Yang HM, Kim D, Roh SW, Kim SK, Jeon BT, Park PJ, Jung WK and Jeon YJ: Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. Environ Toxicol Pharmacol 35: 47-54, 2012.

20. Yu RX, Xu XM, Xu SQ, Jiang ZJ and Yang W: Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via STAT3 pathway. Food Chem Toxicol 49: 285-1291, 2011.

21. Shimada T and Fujiki-Kuniyama Y: Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 95: 1-6, 2004.

22. Kang D, Heo SJ, Ahn G, Kang MC, Kim D, Roh SW, Kim SK, Jeon BT, Park PJ, Jung WK and Jeon YJ: Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. Environ Toxicol Pharmacol 35: 29-36, 2013.

23. Wang H and Leung LK: The carotenoid lycopene differentially regulates phase I and II enzymes in dimethylbenz[a]anthracene-induced MCF-7 cells. Nutrition 26: 1181-1187, 2010.

24. Gradelet S, Astorg P, Le Bon AM, Bergès R and Suschetet M: Modulation of aflatoxin B1 carcinogenicity, genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1A inducers. Cancer Lett 144: 221-232, 1999.

25. Kim KN, Ahn G, Heo SJ, Kang SM, Kang MC, Yang HM, Kim D, Roh SW, Kim SK, Jeon BT, Park PJ, Jung WK and Jeon YJ: Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells. Environ Toxicol Pharmacol 35: 29-36, 2013.

26. Yu RX, Xu XM, Xu SQ, Jiang ZJ and Yang W: Effects of fucoxanthin on proliferation and apoptosis in human gastric adenocarcinoma MGC-803 cells via STAT3 pathway. Eur J Pharmocol 657: 60-10, 2011.

27. Wang H, Chen S, Yu S, Yu X, Ma D, Hu X and Cao X: In vivo induction of apoptosis by fucoxanthin, a marine carotenoid, associated with down-regulating STAT3/EGFR signaling in sarcoma 180 (S180) xenografts-bearing mice. Mar Drugs 10: 2055-2068, 2012.

28. Kim JM, Araki S, Kim DJ, Park CB, Takasuka N, Baba-Toriyama H, Ota T, Nir Z, F Khachik, Shimidzu N, Tanaka Y, Osawa T, Uraji T, Murakoshi M, Nishino H and Tsuda H: Chemopreventive effects of carotenoids and curcumin on mouse colon carcinogenesis after 1,2-dimethylhydrazine treatment. Carcinogenesis 29: 1-8, 2010.

29. Gradelet S, Astorg P, Le Bon AM, Bergès R and Suschetet M: Effects of fucoxanthin, a marine carotenoid, on N-ethyl-N'‑nitro‑N‑nitrosoguanidine‑induced mouse duodenal carcinogenesis. Cancer Lett 68: 159-168, 1993.

30. Cioliolo HP, MacDonald CJ and Yeh GC: Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androstene-17-one. Cancer Res 62: 3685-3690, 2002.

31. Goralczyk R: Beta-carotene and lung cancer in smokers: review of hypotheses and status of research. Nutr Cancer 61: 767-774, 2009.